Evidence map›Paper›PMID 33401004›Full record

ArticlePharmacological research2021

Novel curcumin analog (cis-trans curcumin) as ligand to adenosine receptors A

Luke J Hamilton, Michaela Walker, Mahesh Pattabiraman, Haizhen A Zhong, Brandon Luedtke, Surabhi Chandra

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmacological research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Curcumin Stereoisomer, Cis-Trans Curcumin, as a Novel Ligand to APharmaceuticals (Basel, Switzerland) · 2023
    Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Luke J HamiltonDepartment of Biology, University of Nebraska-Kearney, United States.
Michaela WalkerDepartment of Biology, University of Nebraska-Kearney, United States.
Mahesh PattabiramanDepartment of Chemistry, University of Nebraska-Kearney, United States.
Haizhen A ZhongDepartment of Chemistry, University of Nebraska-Omaha, United States.
Brandon LuedtkeDepartment of Biology, University of Nebraska-Kearney, United States.
Surabhi ChandraDepartment of Biology, University of Nebraska-Kearney, United States. Electronic address: chandras2@unk.edu.

Funding

UNMC Structural Biology CoreP20GM103427 · NIGMS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI PAUL L SORGEN · 2012 to 2026
$59.2M
Tracking and Evaluation CoreU54GM115458 · NIGMS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI GUDA, CHITTIBABU · 2016 to 2025
$42.8M
NIGMS NIH HHS P20 GM103427NIGMS NIH HHS U54 GM115458
6 · The paper itself

Abstract

All four of the adenosine receptor (AR) subtypes mediate pain and have been targeted by pharmacologists to generate new therapeutics for chronic pain. The vanilloid phytochemicals, which include curcumin, capsaicin, and gingerol, have been shown to alleviate pain. However, there is little to no literature on the interaction of vanilloid phytochemicals with ARs. In this study, photochemical methods were used to generate a novel isomer of curcumin (cis-trans curcumin or CTCUR), and the interactions of both curcumin and CTCUR with the two G

Indexed as

Binding, CompetitiveCurcuminCyclic AMPHEK293 CellsHumansIsomerismLigandsMicroscopy, ConfocalMolecular Docking SimulationProtein Structure, TertiaryReceptor, Adenosine A2AReceptor, Adenosine A2BCurcuminCyclic AMPLigandsReceptor, Adenosine A2AReceptor, Adenosine A2B5'-N-Ethylcarboxamidoadenosine (PubChem CID: 4400)AdenosineAdenosine receptor A(2A)Adenosine receptor A(2B)Chronic painCis-Trans curcumin (PubChem CID: 969516)CurcuminCurcumin (PubChem CID: 969516)G(stimulatory)

Identifiers

PMID33401004
PMCPMC7979524

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.